IP Library › Granted Patent US 12,458,689
Granted Patent B2
US 12,458,689 · App. 18/596,916 · Granted Nov 4, 2025

Patent

Inventors: Robert G. K. Donald (South Orange, NJ); Rosalind Pan (Morris Plains, NJ)
Assignee: Pfizer Inc.
A61K39/0258A61K39/0266A61K39/385A61P31/04A61P37/04A61K2039/6031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,689
App. No.
18/596,916
Granted
Nov 4, 2025
Kind
B2
Abstract

This invention provides a polypeptide derived from E. coli or a fragment thereof, including compositions and methods thereof. In one embodiment, the compositions comprise a polypeptide derived from E. coli or a fragment thereof, and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides or conjugates thereof. In a further aspect, the compositions further comprise modified O-polysaccharide molecules derived from Klebsiella pneumoniae or conjugates thereof.

Claims (14)

1 . A method of eliciting an immune response against Escherichia coli ( E. coli ) and Klebsiella pneumoniae ( K. pneumoniae ) in a subject, comprising administering to the subject an effective amount of a composition comprising (a) a saccharide derived from E. coli comprising a structure selected from the group consisting of Formula O1A, Formula O2, Formula O6: K2, Formula O6: K13, Formula O6: K15, Formula O6: K54, Formula O25b, and Formula O75, wherein n is an integer consisting of 31 to 100 in the Formula for each saccharide molecule; and (b) a saccharide derived from a K. pneumoniae type selected from the group consisting of O3, O4, O5, O7, O8, and O12.

2 . The method according to claim 1 , wherein the K. pneumoniae saccharide is derived from K. pneumoniae type O4.

3 . The method according to claim 1 , wherein the K. pneumoniae saccharide is derived from K. pneumoniae type O7.

4 . The method according to claim 1 , wherein the K. pneumoniae saccharide is derived from K. pneumoniae type O3.

5 . The method according to claim 1 , wherein the K. pneumoniae saccharide is derived from K. pneumoniae type O5.

6 . The method according to claim 1 , wherein the composition comprises a saccharide derived from K. pneumoniae type O3 and a saccharide derived from K. pneumoniae type O5.

7 . The method according to claim 1 , wherein the saccharide derived from K. pneumoniae is conjugated to a carrier protein; and the saccharide derived from E. coli is conjugated to a carrier protein.

8 . The method according to claim 1 , wherein the E. coli saccharide further comprises a 3-deoxy-d-manno-oct-2-ulosonic acid (KDO) moiety.

9 . The method according to claim 7 , wherein the carrier protein conjugated to the saccharide derived from E. coli is selected from the group consisting of CRM 197 , diphtheria toxin fragment B(DTFB), DTFB C8, Diphtheria toxoid (DT), tetanus toxoid (TT), fragment C of TT, pertussis toxoid, cholera toxoid, exotoxin A from Pseudomonas aeruginosa ( P. aeruginosa ), detoxified Exotoxin A of P. aeruginosa (EPA), maltose binding protein (MBP), detoxified hemolysin A of Staphylococcus aureus , clumping factor A, clumping factor B, Cholera toxin B subunit (CTB), Streptococcus pneumoniae Pneumolysin, detoxified variants of Streptococcus pneumoniae Pneumolysin, Campylobacter jejuni ( C. jejuni ) AcrA, and C. jejuni natural glycoproteins.

10 . The method according to claim 7 , wherein the carrier protein conjugated to the saccharide derived from K. pneumoniae is selected from the group consisting of CRM 197 , diphtheria toxin fragment B (DTFB), DTFB C8, Diphtheria toxoid (DT), tetanus toxoid (TT), fragment C of TT, pertussis toxoid, cholera toxoid, exotoxin A from Pseudomonas aeruginosa ( P. aeruginosa ), detoxified Exotoxin A of P. aeruginosa (EPA), maltose binding protein (MBP), detoxified hemolysin A of Staphylococcus aureus , clumping factor A, clumping factor B, Cholera toxin B subunit (CTB), Streptococcus pneumoniae Pneumolysin, detoxified variants of Streptococcus pneumoniae Pneumolysin, Campylobacter jejuni AcrA, and C. jejuni natural glycoproteins.

11 . The method according to claim 1 , wherein the immune response comprises opsonophagocytic antibodies against E. coli.

12 . The method according to claim 1 , wherein the immune response protects the subject from an E. coli infection.

13 . The method according to claim 1 , wherein the immune response comprises opsonophagocytic antibodies against K. pneumoniae.

14 . The method according to claim 1 , wherein the immune response protects the subject from a K. pneumoniae infection.

Continuity (4)
Division 17180959 · Feb 22, 2021
Provisional Application 63144058 · Feb 1, 2021
Provisional Application 62980433 · Feb 23, 2020
Related Publication 20240325513A1 · Oct 3, 2024
References Cited (21)
US 20030199071A1 · Langermann et al. · 2003 [cited by applicant]
US 20160136285A1 · Gozdziewicz et al. · 2016 [cited by applicant]
US 20210221856A1 · Grijpstra et al. · 2021 [cited by applicant]
US 20210268095A1 · Donald et al. · 2021 [cited by applicant]
WO 9520657A1 · 1995 [cited by applicant]
WO WO2006113528A2 · 2006 [cited by applicant]
WO WO2015052344A1 · 2015 [cited by examiner]
Franco et al. 1998 (The Wzz (C1d) Protein in [cited by examiner]
Murray et al. 2003 (Regulation of [cited by examiner]
Stenutz et al. 2006 (The structures of [cited by examiner]
Aucken & Pitt, “Serological relationships of the O antigens of Klebsiella pneumoniae 05, [cited by applicant]
Costantino et al, “The design of semi-synthetic and synthetic glycoconjugate vaccines”, Expert Opinion Drug Discovery 6(10):1045-1066 (2011). [cited by applicant]
Greenspan et al, “Defining epitopes: It's not as easy as it seems”, Nature Biotechnology 17:936-938 (1999). [cited by applicant]
Rojas-Macias et al, “Development of the ECODAB into a relational database for [cited by applicant]
Sarshar et al, “FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens”, Antibiotics 9(7):397 (2020). [cited by applicant]
Yakovenko et al, “Inactive conformation enhances binding function in physiological conditions”, PNAS 112(32):9884-9889 (2015). [cited by applicant]
Kido, N., et al., “Inhibition by Succinyl Concanavalin A of Strong Adjuvant Activity of Lipopolysaccharides Which Possess Mannans as the O-Specific Polysaccharide Chains”, Cellular Immunology, 1985, 92(2):328-337. [cited by applicant]
Kido, N., et al., “Potent Adjuvant Action of Lipopolysaccharides Possessing the O-Specific Polysaccharide Moieties Consisting of Mannans in Antibody Response against Protein Antigen”, Cellular Immunology, 1985, 91:52-59. [cited by applicant]
Micoli, F., et al., “Potential targets for next generation antimicrobial glycoconjugate vaccines”, FEMS Microbiology Reviews, 2018, 42(3):388-423. [cited by applicant]
Sugiyama, T., et al., “Generation of [cited by applicant]
Vinogradov, E., et al., “The structure of the core region of the lipopolysaccharide from Klebsiella pneumoniae 03: 3-Deoxy-alpha-D-manno-octulosonic acid (alpha-Kdo) residue in the outer part of the core, a common struc… [cited by applicant]